Critical Outcome Technologies Inc. announced today the launch of ROSALIND™, a smart data platform designed to provide personalized drug treatment options for cancer patients based on the genetic mutation and expression profile of an individual’s tumor. Using advanced algorithms for dealing with big data problems, ROSALIND makes it possible to evaluate what available drug treatments may be effective for an individual’s specific cancer while minimizing potential side effects using advanced algorithms.
“We believe ROSALIND will empower physicians to make efficient individual patient treatment decisions based on an individual’s cancer gene mutation and expression profile,” said Dr. Wayne Danter, President and CEO. “Leveraging the rapid advancements in genomic technologies and our understanding of the causal relationship between gene mutations and cell signaling abnormalities in cancer cells, ROSALIND is an exciting opportunity to make truly personalized cancer care a reality. Our vision for ROSALIND is that more personalized cancer treatments will lead to better patient outcomes and, ultimately, a lower cost of cancer therapy.”
At the core of the proprietary ROSALIND platform is a dynamic, programmable computer simulation of how cell signaling pathways are altered by specific gene mutations that are associated with specific types of cancers.
ROSALIND has successfully undergone initial validation but now requires further real world testing. Assessments suggesting optimal personalized drugtreatment options are immediately available for physicians to order free of charge during this validation phase. In a recent system stress test, ROSALIND evaluated 1.4 million drug combinations and provided multiple potential treatment options for patients in less than 90 minutes.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
